NCT01365208

New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer

Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 70 (actual)
• Sponsor: Chinese University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The combination of pEBV DNA (half-life) and PET-CT following 1 course of chemotherapy allow earlier and more detection of drug response in advanced NPC than RECIST method, in patients with previously untreated advanced NPC who will receive platinum-based chemotherapy. This study will also determine if this new method can predict survival in these patients. This study may have far-reaching impact on drug development in NPC as it may offer a more optimal way of evaluating drug efficacy in clinical trials and also in clinical management.

Conditions

• Advanced Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Chemotherapy	platinum-based chemotherapy

Timeline

• Start date: 2011-07-01
• Primary completion: 2017-03-03
• Completion: 2017-03-03
• First posted: 2011-06-03
• Last updated: 2017-03-24

Locations

1 site across 1 country: Hong Kong